Is Stryker Corporation (SYK) overvalued? · P/E 35, rev $6.59B
Stryker Corporation (SYK) is a medical devices company listed on NYSE.
This page asks whether Stryker Corporation (SYK) looks expensive on cached numbers — not a short thesis.
Latest reported SYK revenue for 2026-06-30 was $6.59B. Net income was $1.28B. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
SYK currently screens at market cap $115.45B and trailing P/E 34.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SYK 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SYK stock page for the full model, not this heading.
Not investment advice.